Second Genome, Janssen Biotech Partner to Develop Ulcerative Colitis Treatment

Second Genome, San Bruno, Calif.-based microbiome therapeutic products company, has announced a partnership with Janssen Biotech designed to develop a novel treatment for ulcerative colitis.

Advertisement

Johnson & Johnson Innovation Center and the Immunology Therapeutic Area of Janssen Research & Development will fund the research.

More Articles on Gastroenterology:
8 Statistics on Annual & Hourly Gastroenterologist Compensation
American College of Gastroenterology Responds to ‘The $2.7T Medical Bill’
Dr. Leslie Schoppe Joins Brownwood Regional Medical Center

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.